Search results
Showing 736 to 750 of 1032 results for drug therapy
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.
This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.
Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.
Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.
View recommendations for IPG615Show all sections
Transpupillary thermotherapy for age-related macular degeneration (IPG58)
Evidence-based recommendations on transpupillary thermotherapy for age-related macular degeneration. This involves using a laser to heat and seal up the blood vessels that are causing the problems.
View recommendations for IPG58Show all sections
Sections for IPG58
Evidence-based recommendations on radiotherapy for age-related macular degeneration. This involves using radiation to destroy the new blood vessels, with the aim of slowing down sight loss.
View recommendations for IPG49Show all sections
Sections for IPG49
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .